Joseph Geradts

Joseph Geradts

Adjunct Professor in the Department of Pathology

Dr. Geradts' primary research focus is on the molecular pathology of breast cancer. His laboratory uses genomic profiling strategies to identify novel candidate breast cancer genes. Dr. Geradts is also interested in biomarker development. He directs the Tissue Core of Duke's Breast Cancer SPORE and collaborates on numerous breast cancer related research projects with other investigators at Duke and elsewhere.

Appointments and Affiliations

  • Adjunct Professor in the Department of Pathology

Contact Information

  • Office Location: Rm 3108 Meyer Ward, Department of Pathology, Durham, NC 27710
  • Office Phone: +1 919 684 2452
  • Email Address:


  • State University of New York, Buffalo, 2005
  • University of North Carolina, Chapel Hill, 1993
  • National Institutes of Health, 1991
  • Stanford University, 1990
  • University of California San Francisco, School of Medicine, 1989
  • M.D. The University of Chicago, 1987
  • M.A. University of California, Berkeley, 1984

In the News

Representative Publications

  • Barry, WT; Kernagis, DN; Dressman, HK; Griffis, RJ; Hunter, JD; Olson, JA; Marks, JR; Ginsburg, GS; Marcom, PK; Nevins, JR; Geradts, J; Datto, MB, Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome., J Clin Oncol, vol 28 no. 13 (2010), pp. 2198-2206 [10.1200/JCO.2009.26.7245] [abs].
  • Sood, AK; Wang, J; Mhawech-Fauceglia, P; Jana, B; Liang, P; Geradts, J, Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis., Cancer Epidemiol Biomarkers Prev, vol 18 no. 6 (2009), pp. 1899-1903 [10.1158/1055-9965.EPI-09-0055] [abs].
  • Brown, JQ; Wilke, LG; Geradts, J; Kennedy, SA; Palmer, GM; Ramanujam, N, Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo., Cancer Res, vol 69 no. 7 (2009), pp. 2919-2926 [10.1158/0008-5472.CAN-08-3370] [abs].
  • Ramanujam, N; Brown, J; Bydlon, TM; Kennedy, SA; Richards, LM; Junker, MK; Gallagher, J; Barry, WT; Wilke, LG; Geradts, J, Quantitative spectral reflectance imaging device for intraoperative breast tumor margin assessment., Annu Int Conf IEEE Eng Med Biol Soc, vol 2009 (2009), pp. 6554-6556 [10.1109/IEMBS.2009.5334501] [abs].
  • Millikan, RC; Newman, B; Tse, C-K; Moorman, PG; Conway, K; Dressler, LG; Smith, LV; Labbok, MH; Geradts, J; Bensen, JT; Jackson, S; Nyante, S; Livasy, C; Carey, L; Earp, HS; Perou, CM, Epidemiology of basal-like breast cancer., Breast Cancer Res Treat, vol 109 no. 1 (2008), pp. 123-139 [10.1007/s10549-007-9632-6] [abs].
  • Sood, AK; Saxena, R; Groth, J; Desouki, MM; Cheewakriangkrai, C; Rodabaugh, KJ; Kasyapa, CS; Geradts, J, Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression., Hum Pathol, vol 38 no. 11 (2007), pp. 1628-1638 [10.1016/j.humpath.2007.03.010] [abs].
  • Huang, H; Sossey-Alaoui, K; Beachy, SH; Geradts, J, The tetraspanin superfamily member NET-6 is a new tumor suppressor gene., J Cancer Res Clin Oncol, vol 133 no. 10 (2007), pp. 761-769 [10.1007/s00432-007-0221-1] [abs].
  • Carey, LA; Perou, CM; Livasy, CA; Dressler, LG; Cowan, D; Conway, K; Karaca, G; Troester, MA; Tse, CK; Edmiston, S; Deming, SL; Geradts, J; Cheang, MCU; Nielsen, TO; Moorman, PG; Earp, HS; Millikan, RC, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study., JAMA, vol 295 no. 21 (2006), pp. 2492-2502 [10.1001/jama.295.21.2492] [abs].
  • Varma, G; Varma, R; Huang, H; Pryshchepava, A; Groth, J; Fleming, D; Nowak, NJ; McQuaid, D; Conroy, J; Mahoney, M; Moysich, K; Falkner, KL; Geradts, J, Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York., Br J Cancer, vol 93 no. 6 (2005), pp. 699-708 [10.1038/sj.bjc.6602784] [abs].
  • Huang, H; Groth, J; Sossey-Alaoui, K; Hawthorn, L; Beall, S; Geradts, J, Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors., Clin Cancer Res, vol 11 no. 12 (2005), pp. 4357-4364 [10.1158/1078-0432.CCR-04-2107] [abs].
  • Geradts, J, Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer., Methods Mol Med, vol 74 (2003), pp. 89-99 [10.1385/1-59259-323-2:89] [abs].
  • Wilson, KS; Roberts, H; Leek, R; Harris, AL; Geradts, J, Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues., Am J Pathol, vol 161 no. 4 (2002), pp. 1171-1185 [10.1016/S0002-9440(10)64394-5] [abs].